<p>RiverFront Investment Group LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 35.4%。该机构投资者在该季度出售了 4,777 股后，持有该医疗技术公司 8,719 股股票。RiverFront Investment Group LLC 在史赛克的持股在最近的报告期末价值为 3,065,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他几家大型投资者也最近调整了对该公司的持股。Sapient Capital LLC 在第四季度将其在史赛克的持股增加了 1.6%。Sapient Capital LLC 目前持有 4,897 股该医疗技术公司的股票，价值 1,738,000 美元，此前在上个季度增持了 76 股。北达科他州投资委员会在第四季度购买了史赛克的新股份，价值约 4,149,000 美元。Elyxium Wealth LLC 在第四季度购买了史赛克的新股份，价值约 155,000 美元。Rossmore Private Capital 在第四季度将其在史赛克的持股增加了 12.2%。Rossmore Private Capital 目前持有 19,561 股该医疗技术公司的股票，价值 6,892,000 美元，此前在上个季度增持了 2,122 股。最后，Soltis Investment Advisors LLC 在第四季度将其在史赛克的持股增加了 10.9%。Soltis Investment Advisors LLC 目前持有 2,264 股该医疗技术公司的股票，价值 796,000 美元，此前在上个季度增持了 222 股。当前 77.09% 的股票由机构投资者持有。</p>
<h2>分析师评级上调与下调</h2>
<p>SYK 一直是多份研究分析师报告的主题。William Blair 在 3 月 5 日的报告中重申了对史赛克股票的 “跑赢大盘” 评级。Canaccord Genuity Group 将史赛克股票的目标价从 435.00 美元下调至 400.00 美元，并在 5 月 1 日的报告中对该股票给予 “买入” 评级。摩根大通将史赛克股票的目标价从 445.00 美元下调至 400.00 美元，并在 5 月 1 日的报告中对该股票给予 “增持” 评级。Needham &amp; Company LLC 将史赛克股票的目标价从 454.00 美元下调至 418.00 美元，并在 5 月 1 日的报告中对该股票给予 “买入” 评级。最后，德意志银行在 5 月 1 日的报告中设定了 315.00 美元的目标价。十六位投资分析师对该股票给予了 “买入” 评级，六位分析师对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 395.48 美元。</p>
<ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
<p><strong>查看我们关于 SYK 的最新研究报告</strong></p>
<h2>内部人士下注</h2>
<p>在相关消息中，副总裁 M Kathryn Fink 于 5 月 11 日在一笔交易中出售了 5,220 股公司的股票。这些股票的平均售价为 283.85 美元，总价值为 1,481,697.00 美元。交易完成后，该副总裁持有 13,137 股公司的股票，价值约为 3,728,937.45 美元。这笔交易代表了他们持股的 28.44% 的减少。该交易已在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。公司内部人士持有公司股票的 4.60%。</p>
<h2>史赛克股价下跌 0.0%</h2>
<ul>
<li>当心死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
<p>史赛克（NYSE:SYK）周一开盘价为 306.74 美元。该公司的市值为 1,175.9 亿美元，市盈率为 35.50，PEG 比率为 1.93，贝塔值为 0.80。史赛克公司的 12 个月低点为 281.00 美元，12 个月高点为 404.87 美元。该公司的 50 日简单移动平均线为 329.68 美元，200 日简单移动平均线为 351.50 美元。该公司的速动比率为 1.25，流动比率为 2.11，债务与股本比率为 0.62。</p>
<p>史赛克（NYSE:SYK - 获取免费报告）最近于 4 月 30 日发布了其财报。这家医疗技术公司报告第四季度每股收益为 2.60 美元，低于分析师一致预期的 2.98 美元，差额为 0.38 美元。该季度的收入为 60.2 亿美元，而一致预期为 63.4 亿美元。史赛克的净利润率为 13.20%，股本回报率为 23.42%。该公司的季度收入同比增长 2.6%。去年同期，该公司每股收益为 2.84 美元。史赛克已将其 2026 财年的指引设定为每股收益 14.900-15.100。整体来看，研究分析师预测史赛克公司本财年将发布每股收益 14.98 美元。</p>
<h2>史赛克宣布分红</h2>
<p>该公司还最近宣布了一项季度分红，将于 7 月 31 日（星期五）支付。6 月 30 日的登记投资者将获得 0.88 美元的分红。该分红的除息日为 6 月 30 日（星期二）。这相当于每年 3.52 美元的分红，收益率为 1.1%。史赛克的分红支付比率（DPR）为 40.74%。</p>
<h2>关于史赛克</h2>
<p>（免费报告）</p>
<p>史赛克公司是一家全球医疗技术公司，设计、制造和销售广泛的产品和服务，供医院、外科医生办公室和其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和肢体产品）、外科设备和手术室技术（如可视化、导航和电动工具）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 关注火热的分拆和并购领域</li>
<li>随着 AI 存储需求激增，三星加入了 1 万亿美元俱乐部</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
<p>在你考虑史赛克之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而史赛克并不在名单上。</p>
<p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

史赛克

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>RiverFront Investment Group LLC 将其在史赛克（Stryker Corporation，NYSE:SYK）的持股减少了 35.4%，在第四季度出售了 4,777 股，剩余 8,719 股，市值为 3,065,000 美元。其他投资者也调整了他们的持股，其中 Sapient Capital 和 Rossmore Private Capital 的增持幅度显著。史赛克的股票获得了分析师的褒贬不一的评级，市场共识目标价为 395.48 美元。该公司报告第一季度每股收益为 2.60 美元，未达到预期，收入为 60.2 亿美元</p>

<p>RiverFront Investment Group LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 35.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 8,719 shares of the medical technology company's stock after selling 4,777 shares during the quarter. RiverFront Investment Group LLC's holdings in Stryker were worth $3,065,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>RiverFront Investment Group LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在史赛克公司（NYSE:SYK - 免费报告）的持股减少了 35.4%。该机构投资者在该季度出售了 4,777 股后，持有该医疗技术公司 8,719 股股票。RiverFront Investment Group LLC 在史赛克的持股在最近的报告期末价值为 3,065,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Several other large investors also recently modified their holdings of the business. Sapient Capital LLC increased its holdings in shares of Stryker by 1.6% in the fourth quarter. Sapient Capital LLC now owns 4,897 shares of the medical technology company's stock worth $1,738,000 after acquiring an additional 76 shares in the last quarter. North Dakota State Investment Board bought a new stake in shares of Stryker in the fourth quarter worth about $4,149,000. Elyxium Wealth LLC bought a new stake in shares of Stryker in the fourth quarter worth about $155,000. Rossmore Private Capital increased its holdings in shares of Stryker by 12.2% in the fourth quarter. Rossmore Private Capital now owns 19,561 shares of the medical technology company's stock worth $6,892,000 after acquiring an additional 2,122 shares in the last quarter. Finally, Soltis Investment Advisors LLC increased its holdings in shares of Stryker by 10.9% in the fourth quarter. Soltis Investment Advisors LLC now owns 2,264 shares of the medical technology company's stock worth $796,000 after acquiring an additional 222 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者也最近调整了对该公司的持股。Sapient Capital LLC 在第四季度将其在史赛克的持股增加了 1.6%。Sapient Capital LLC 目前持有 4,897 股该医疗技术公司的股票，价值 1,738,000 美元，此前在上个季度增持了 76 股。北达科他州投资委员会在第四季度购买了史赛克的新股份，价值约 4,149,000 美元。Elyxium Wealth LLC 在第四季度购买了史赛克的新股份，价值约 155,000 美元。Rossmore Private Capital 在第四季度将其在史赛克的持股增加了 12.2%。Rossmore Private Capital 目前持有 19,561 股该医疗技术公司的股票，价值 6,892,000 美元，此前在上个季度增持了 2,122 股。最后，Soltis Investment Advisors LLC 在第四季度将其在史赛克的持股增加了 10.9%。Soltis Investment Advisors LLC 目前持有 2,264 股该医疗技术公司的股票，价值 796,000 美元，此前在上个季度增持了 222 股。当前 77.09% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>SYK has been the topic of a number of research analyst reports. William Blair restated an &#34;outperform&#34; rating on shares of Stryker in a report on Thursday, March 5th. Canaccord Genuity Group dropped their price objective on shares of Stryker from $435.00 to $400.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, May 1st. JPMorgan Chase &amp; Co. dropped their price objective on shares of Stryker from $445.00 to $400.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, May 1st. Needham &amp; Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $395.48.</p>
<div class="lb-trans"><p>SYK 一直是多份研究分析师报告的主题。William Blair 在 3 月 5 日的报告中重申了对史赛克股票的 “跑赢大盘” 评级。Canaccord Genuity Group 将史赛克股票的目标价从 435.00 美元下调至 400.00 美元，并在 5 月 1 日的报告中对该股票给予 “买入” 评级。摩根大通将史赛克股票的目标价从 445.00 美元下调至 400.00 美元，并在 5 月 1 日的报告中对该股票给予 “增持” 评级。Needham &amp; Company LLC 将史赛克股票的目标价从 454.00 美元下调至 418.00 美元，并在 5 月 1 日的报告中对该股票给予 “买入” 评级。最后，德意志银行在 5 月 1 日的报告中设定了 315.00 美元的目标价。十六位投资分析师对该股票给予了 “买入” 评级，六位分析师对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 395.48 美元。</p>
</div><ul>
<li>Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
</div><p><strong>View Our Latest Research Report on SYK</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SYK 的最新研究报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, VP M Kathryn Fink sold 5,220 shares of the firm's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company's stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，副总裁 M Kathryn Fink 于 5 月 11 日在一笔交易中出售了 5,220 股公司的股票。这些股票的平均售价为 283.85 美元，总价值为 1,481,697.00 美元。交易完成后，该副总裁持有 13,137 股公司的股票，价值约为 3,728,937.45 美元。这笔交易代表了他们持股的 28.44% 的减少。该交易已在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。公司内部人士持有公司股票的 4.60%。</p>
</div><h2>Stryker Trading Down 0.0%</h2>
<div class="lb-trans"><h2>史赛克股价下跌 0.0%</h2>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>当心死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
</div><p>Shares of NYSE:SYK opened at $306.74 on Monday. The firm has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company's fifty day simple moving average is $329.68 and its 200 day simple moving average is $351.50. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK）周一开盘价为 306.74 美元。该公司的市值为 1,175.9 亿美元，市盈率为 35.50，PEG 比率为 1.93，贝塔值为 0.80。史赛克公司的 12 个月低点为 281.00 美元，12 个月高点为 404.87 美元。该公司的 50 日简单移动平均线为 329.68 美元，200 日简单移动平均线为 351.50 美元。该公司的速动比率为 1.25，流动比率为 2.11，债务与股本比率为 0.62。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）最近于 4 月 30 日发布了其财报。这家医疗技术公司报告第四季度每股收益为 2.60 美元，低于分析师一致预期的 2.98 美元，差额为 0.38 美元。该季度的收入为 60.2 亿美元，而一致预期为 63.4 亿美元。史赛克的净利润率为 13.20%，股本回报率为 23.42%。该公司的季度收入同比增长 2.6%。去年同期，该公司每股收益为 2.84 美元。史赛克已将其 2026 财年的指引设定为每股收益 14.900-15.100。整体来看，研究分析师预测史赛克公司本财年将发布每股收益 14.98 美元。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史赛克宣布分红</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is 40.74%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 7 月 31 日（星期五）支付。6 月 30 日的登记投资者将获得 0.88 美元的分红。该分红的除息日为 6 月 30 日（星期二）。这相当于每年 3.52 美元的分红，收益率为 1.1%。史赛克的分红支付比率（DPR）为 40.74%。</p>
</div><h2>About Stryker</h2>
<div class="lb-trans"><h2>关于史赛克</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.</p>
<div class="lb-trans"><p>史赛克公司是一家全球医疗技术公司，设计、制造和销售广泛的产品和服务，供医院、外科医生办公室和其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和肢体产品）、外科设备和手术室技术（如可视化、导航和电动工具）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li>
<li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li>
<li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li>
<li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>当博通市值超过 2 万亿美元时，私人信贷巨头想要参与</li>
<li>通过这些 ETF 关注火热的分拆和并购领域</li>
<li>随着 AI 存储需求激增，三星加入了 1 万亿美元俱乐部</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑史赛克之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而史赛克并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

RiverFront Investment Group LLC Sells 4,777 Shares of Stryker Corporation $SYK

Market Beat

摩根大通

德意志银行

Robinhood

Mercury

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

RiverFront Investment Group LLC 出售了 4,777 股史赛克公司 $SYK